Innovation

Morinaga Milk supports the healthy life of people of all ages, from babies to seniors, through R&D to make use of " the great power of milk."

Morinaga Milk has consistently worked to "support people's health with the great power of milk r" since its founding. Our R&D efforts to strengthen this support focus on the properties and powers of milk from various angles.
Our largest research topic at Morinaga Milk has been the development of infant formula. We have been creating processes to bring the nutritional components in infant formula close to those in breast milk while studying functional ingredients to support the healthy growth of babies. The understanding we gain on the functionality of milk can be applied not only for babies, but for the health of all people.
We will extend our research to contribute to the health of our customers as a provider of delicious dairy products for daily consumption.

Bifidobacterium breve M-16V for Low-birthweight Infants

Normally, bifidobacteria makes up more than 90% of the intestinal flora of a healthy baby. Yet the intestinal tract tends to be undeveloped in a low-birthweight baby, especially a baby with an extremely low birthweight of less than 1,500g. An undeveloped intestinal tract is often unable to colonize bifidobacteria, with increase of the opportunity for the growth of unfavorable bacteria such as Escherichia coli and Staphylococcus aureus. Collaborative studies by Morinaga Milk and university hospitals have found that the administration of one proprietary strain of Bifidobacterium breve M-16V to low- or extremely-low-birthweight infants promotes the formation of bifidobacteria-predominant intestinal microflora and protects newborns from the risks of necrotizing enterocolitis (NEC) and sepsis. Bifidobacterium breve M-16V is now offered to more than 120 facilities nationwide, including NICUs (neonatal intensive care unit) and pediatrics departments, as a probiotic support to the healthy growth of babies. The benefits of Bifidobacterium breve M-16V for low-birthweight infants have been also known worldwide through academic societies and dissertations. The probiotic has been used in NICUs in Australia since 2012 and has been introduced at NICUs in New Zealand and Singapore more recently. Morinaga Milk plans to continue supporting the healthy growth of babies and children all over the world.

Bifidobacterium breve M-16V is also used in Australia, New Zealand, and Singapore.

TOP